These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 35726803)
1. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma. Varma G; Wang J; Diefenbach C Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803 [TBL] [Abstract][Full Text] [Related]
2. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma. Walji M; Assouline S Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586 [TBL] [Abstract][Full Text] [Related]
3. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Bourbon E; Salles G Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972 [TBL] [Abstract][Full Text] [Related]
4. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Malecek MK; Watkins MP; Bartlett NL Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753 [TBL] [Abstract][Full Text] [Related]
5. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619 [TBL] [Abstract][Full Text] [Related]
6. Polatuzumab Vedotin: a New Target for B Cell Malignancies. Choi Y; Diefenbach CS Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360 [TBL] [Abstract][Full Text] [Related]
7. Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma? Ghione P; Salles G Haematologica; 2024 Sep; 109(9):2802-2809. PubMed ID: 38813707 [TBL] [Abstract][Full Text] [Related]
9. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma. Camus V; Tilly H Future Oncol; 2021 Jan; 17(2):127-135. PubMed ID: 32954807 [TBL] [Abstract][Full Text] [Related]
10. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489 [TBL] [Abstract][Full Text] [Related]
11. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429 [TBL] [Abstract][Full Text] [Related]
12. Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Dere RC; Beardsley RL; Lu D; Lu T; Ku GH; Man G; Nguyen V; Kaur S Front Immunol; 2023; 14():1119510. PubMed ID: 37063860 [TBL] [Abstract][Full Text] [Related]
13. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412 [TBL] [Abstract][Full Text] [Related]
15. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Amaya ML; Jimeno A; Kamdar M Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823 [TBL] [Abstract][Full Text] [Related]
16. Polatuzumab Vedotin: First Global Approval. Deeks ED Drugs; 2019 Sep; 79(13):1467-1475. PubMed ID: 31352604 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG). Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings. Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111 [TBL] [Abstract][Full Text] [Related]
19. Treatment strategies for patients with diffuse large B-cell lymphoma. Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930 [TBL] [Abstract][Full Text] [Related]
20. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]